视网膜母细胞瘤化疗耐药的研究进展  

Advance in the chemotherapy resistance of retinoblastoma

作　　者：俞依琳 葛盛芳[1] 范佳燕[1] Yi-Lin Yu;Sheng-Fang Ge;Jia-Yan Fan(Department of Ophthalmology,Shanghai Ninth People s Hospital,Shanghai Jiaotong University School of Medicine,Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology,Shanghai 200011,China)

机构地区：[1]上海交通大学医学院附属第九人民医院眼科上海市眼眶病眼肿瘤重点实验室,中国上海市200011

出　　处：《国际眼科杂志》2023年第10期1653-1657,共5页International Eye Science

基　　金：国家自然科学基金面上项目(No.1227050738)。

摘　　要：视网膜母细胞瘤(retinoblastoma,RB)是儿童最常见的眼内恶性肿瘤,化疗是目前治疗RB最常用的方法,包括静脉化疗、动脉化疗和玻璃体腔化疗。然而,RB的化疗耐药时有发生,是导致RB患者保眼治疗失败的主要原因。因此,探索RB化疗耐药的发生发展机制、寻找RB治疗新策略及药物联合治疗的新方法具有重要临床意义。本文综述了RB细胞可通过ATP结合盒式蛋白(ABC转运蛋白)、非编码RNA、表观遗传学修饰、自噬、上皮-间充质转化、细胞外基质改变等多种途径获得化疗耐药性,并对其潜在的治疗靶点或药物进行总结,以期为RB化疗耐药性的进一步研究提供参考。Retinoblastoma(RB)is the most common intraocular malignant tumor of children.Chemotherapy is a preferred method in RB treatment,which includes intravenous chemotherapy,intra-arterial chemotherapy and intravitreal chemotherapy.However,the occurrence of chemotherapy resistance often leads to the failure of eye-preserving treatment in RB patients.Therefore,exploring the mechanism of the occurrence of chemotherapy resistance and searching for new strategies and combined medicines for RB treatment are of great clinical significance.This article reviews that RB cells obtain chemotherapy resistance through ATP binding cassette protein(ABC transporter),non-coding RNA,epigenetics modification,autophagy,epithelial mesenchymal transformation,extracellular matrix changes and other ways,and the potential therapeutic targets for chemotherapy resistance are also summarized,in the hope of providing some references for further research on chemotherapy resistance of RB.

关 键 词：视网膜母细胞瘤 化疗耐药性 肿瘤治疗 

分 类 号：R739.7[医药卫生—肿瘤]